Shire plc (SHPG): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

By
A A A

Summary:
Shire reported third-quarter 2014 earnings (excluding special items and amortization) of $2.93 per ADS, up from $1.83 per ADS in the year-ago quarter and beating the Zacks Consensus Estimate of $2.47. Quarterly revenues increased 31.7% to $1.6 billion, beating the Zacks Consensus Estimate of $1.5 billion. The increase in revenues was driven by growth in the Rare Diseases business unit. We are encouraged by the company's third-quarter results. The subsequent increase in guidance is encouraging as well. With AbbVie terminating its acquisition offer in Oct 2014, we expect Shire to focus on its existing drugs and pipeline. We believe the company's efforts to build a leaner organization with focus on rare diseases should lead to improved margins.

Overview:

Founded in 1986, Dublin-based Shire is a specialty biopharmaceutical company catering to diverse medical needs through research and development, manufacture, sale and distribution of pharmaceutical products.

Shire repositioned its business in 2013, undertaking a realignment program with strategic focus on rare diseases and greater operational discipline. With an aim to reduce overlap, Shire has merged its three autonomous divisions into one. Shire realigned its business structure to drive growth and innovation. As per the strategy, Shire has an "In-Line" marketed product group and a Pipeline Group, with centralized corporate functions. The In-Line marketed products group consist of five business lines, which will focus on commercial delivery Rare Diseases, Neuroscience (formerly Behavioral Health), Gastrointestinal (GI), Regenerative Medicine (RM) and Internal Medicine (with a focus on Adderall XR, Fosrenol and Xagrid) . The Pipeline Group consists of Research & Development (R&D) and Business Development (BD). The unit focuses on late-stage development programs with pre-clinical development focus being primarily on rare diseases, led by a single R&D organization. The BD unit focuses on identifying later-stage development programs and in-market products in target specialist areas. Further, Shire will expand its footprint in Asia and Latin America with a key focus on Japan, China and Brazil.

For 2013, the company reported revenues of $4.9 billion, up 9% year over year. Product sales of $4.7 billion were up 12% from 2012. Shire also receives royalty revenues which mainly comprise income earned from the sale of the authorized generic version of Adderall XR, 3TC, Zeffix, Fosrenol and others. Income from royalties came in at $153.7 million, down 36% from 2012.


Key Drugs

Indication

Sales in 2013 (in millions of dollars)

Vyvanse

Attention deficit and hyperactivity disorder (ADHD)

$1,227.8

Intuniv

ADHD

$334.9

Lialda

Ulcerative Colitis

$528.9

Pentasa

Ulcerative Colitis

$280.6

Fosrenol

Hyperphosphatemia in end stage renal disease

$183.4

Replagal

Fabry disease

$467.9

Elaprase

Hunter syndrome

$545.6

Vpriv

Gaucher disease

$342.7

Firazyr

hereditary angioedema or HAE

$234.8

Adderall XR

ADHD

$375.4

Xagrid

Essential thrombocythemia

$99.4


Shire plc (SHPG): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SHIRE PLC-ADR (SHPG): Free Stock Analysis Report

To read this article on Zacks.com click here.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Stocks

Referenced Stocks: RM , ADHD , SHPG

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,974,386
  • $17.98 ▲ 0.28%
20,763,901
  • $91.29 ▲ 2.06%
19,110,793
  • $7.26 ▼ 1.22%
18,528,869
    $8.33 unch
18,014,920
  • $4.19 ▼ 1.18%
16,448,919
  • $25.83 ▼ 0.19%
14,748,190
  • $7.60 ▼ 1.43%
14,144,383
  • $112.01 ▼ 0.47%
As of 12/24/2014, 02:12 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com